While on my gardening leave, Claude Code was released. Since then I’ve been relentlessly working with this wonderful, terrible, alien technology. My company focuses on its applications in finance and markets.
- AI
- software
- finance
- biotech
- biosecurity
- politics
Glorious Exploits by Ferdia Lennon
Return of the God Hypothesis by Stephen C. Meyer
Writing
-
Model Difference Infrastructure?
Looking beyond benchmarks to understand how AI models differ.
-
BLISP
Making systematic AI-based alpha research safer, repeatable and easier to inspect.
-
Thoughts on biosecurity
There is a debate about whether biosecurity constitutes a major civilisation risk in the AI era…
More on Substack.
Papers
-
2021
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
Nature · Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. · doi:10.1038/s41586-021-03470-x
-
2021
Genomic epidemiology of a densely sampled COVID-19 outbreak in China
Virus Evolution · Geidelberg L, et al. · doi:10.1093/ve/veaa102
-
2021
Mathematical model impact analysis of a real-life pre-exposure prophylaxis and treatment-as-prevention study among female sex workers in Cotonou, Benin
JAIDS · Geidelberg L, et al. · doi:10.1097/QAI.0000000000002535
More on Google Scholar.
Work
-
2025 – now
Founder, CoEmbark
Software that puts AI to work in finance and markets.
-
2023 – 2025
Portfolio Manager, Brevan Howard
A systematic global equities book with a healthcare tilt.
-
2021 – 2023
Senior Biotechnology Analyst, Brevan Howard
Public and private biotech investing.
-
2017 – 2021
PhD, Imperial College London
Mathematical and evolutionary modelling of epidemics, including SARS-CoV-2 variants and HIV prevention in West Africa.